What is the Purpose of this Study?
This study aims to determine whether a new combination of 2 non-chemotherapy drugs can help patients with advanced non-small cell lung cancer to live longer than the usual approach. (The usual approach is defined as treatment with chemotherapy). Researchers will compare the usual treatment to a study treatment that combines ramucirumab and pembrolizumab, which is an experimental combination of drugs. Participants will be randomly assigned to 1 of 2 study groups. One group will receive the study drugs (ramucirumab and pembrolizumab), and the other will receive the usual treatment option (standard-of-care treatment).
Eligibility
- * Participants must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) which is stage IV or recurrent
- * Participants must have received at least one line of anti-PD-1 or anti-PD-L1 therapy for any stage of NSCLC. Anti-PD-1 or anti-PD-L1 may have been given alone or in combination with other therapy
- * Participants must have experienced disease progression (in the opinion of the treating physician) more than (\>) 84 days following initiation (cycle 1 day 1) of their most recent anti-PD-1 or PD-L1 therapy
- * Participants who received anti-PD-1 or anti-PD-L1 therapy for stage IV or recurrent disease, must have had a best response on anti-PD-1 or anti-PD-L1 therapy of stable, partial response or complete response (in the opinion of the treating physician)
Where can I participate?
- CS Cancer Tarzana : Amy Oppenheim
- CS Cancer at Beverly Hills : Amy Oppenheim
- CS Cancer at Cedars-Sinai Medical Center : Amy Oppenheim
- Hunt Cancer Institute, an Affiliate of Cedars-Sinai Cancer
More about this Clinical Trial
What is the full name of this clinical trial?
S2302: PRAGMATICA - LUNG: A Prospective Randomized Study of Ramucirumab Plus Pembrolizumab versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer